Discovery of rafoxanide as a novel agent for the treatment of non-small cell lung cancer

Non-small cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer cases, is associated with a poor outcome. Rafoxanide is an anthelmintic drug that inhibits tumor growth in certain malignancies. However, its impact on NSCLC remains unknown. In this study, we examined the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Ankang, Liu, Jing, Wang, Yonghui, Zhang, Maoyin, Guo, Yao, Qin, Ying, Liu, Tingya, Men, Yanjuan, Chen, Quangang, Liu, Tingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839764/
https://www.ncbi.nlm.nih.gov/pubmed/36639421
http://dx.doi.org/10.1038/s41598-023-27403-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839764/
https://www.ncbi.nlm.nih.gov/pubmed/36639421
http://dx.doi.org/10.1038/s41598-023-27403-y

Ejemplares similares